ApoA1 Test: The Protein Behind Your Good Cholesterol

Quick answer: An ApoA1 test measures the blood level of apolipoprotein A1, the structural protein that makes HDL (high-density lipoprotein) cholesterol functional. Normal ApoA1 ranges from roughly 120 to 160 mg/dL in women and 110 to 150 mg/dL in men, though labs vary slightly. Low ApoA1 predicts cardiovascular risk more precisely than HDL cholesterol alone, and the ApoB/ApoA1 ratio is now used by cardiologists as one of the sharpest single-number risk tools available.

What is ApoA1 and why does it matter more than HDL?

ApoA1 is the primary protein component of HDL particles, and it is the molecule that actually does the work HDL is credited for. When your lab report shows an HDL of 55 mg/dL, that number tells you the total cholesterol mass riding inside HDL particles. It says nothing about how many particles there are or whether those particles are functioning correctly. ApoA1 tells you something closer to particle quality and reverse cholesterol transport capacity.

HDL works by pulling cholesterol off arterial walls and ferrying it back to the liver for processing, a process called reverse cholesterol transport. ApoA1 initiates that process by activating ABCA1, a cell membrane transporter that loads cholesterol onto nascent HDL particles. Without adequate ApoA1, HDL particles cannot be assembled or recharged efficiently.

A person can have a numerically normal HDL and still have low ApoA1 if those HDL particles are cholesterol-rich but protein-poor, a pattern seen in metabolic syndrome and type 2 diabetes. That combination, called dysfunctional HDL, carries meaningful cardiovascular risk that a standard lipid panel will completely miss. The best biomarkers to test for heart risk increasingly include ApoA1 alongside ApoB for exactly this reason.

ApoA1 Milano: the variant that rewrote the story

One reason cardiologists stopped treating HDL as a simple higher-is-better number is a natural mutation called ApoA1 Milano. It was discovered in a small community in northern Italy where carriers have strikingly low HDL and ApoA1 on paper, yet unusually little atherosclerosis and long lifespans. The variant produces a structurally altered ApoA1 that appears to clear cholesterol from artery walls efficiently per particle. The lesson is not that low ApoA1 is fine, because for most people it clearly is not, but that function can matter as much as concentration. It is the clearest real-world proof that what an HDL particle does is not fully captured by how much cholesterol or protein you can measure inside it.

ApoA1 normal range: what the numbers actually mean

Reference ranges differ slightly by laboratory and assay, but the consensus from major clinical labs in the US runs as follows:

Group	Optimal ApoA1	Borderline Low	Low (elevated risk)
Adult women	120 to 160 mg/dL	100 to 119 mg/dL	Below 100 mg/dL
Adult men	110 to 150 mg/dL	90 to 109 mg/dL	Below 90 mg/dL
Children (5 to 17)	110 to 175 mg/dL	90 to 109 mg/dL	Below 90 mg/dL

Women consistently run higher ApoA1 than men, a gap that widens after puberty and narrows after menopause. Estrogen upregulates ApoA1 gene expression and reduces its clearance from circulation. This is one biological reason premenopausal women have lower cardiovascular event rates than age-matched men, even when LDL levels are similar.

At the high end, very high ApoA1 (above 180 mg/dL) is generally considered favorable. There is no established upper threshold for harm, unlike ApoB where higher is consistently worse.

ApoB/ApoA1 ratio: the number cardiologists watch most closely

The ApoB/ApoA1 ratio compresses the two sides of the cardiovascular equation into one number: atherogenic burden (ApoB) divided by atheroprotective capacity (ApoA1). Lower is better. Most guidelines target a ratio below 0.8 for average-risk adults and below 0.7 for those with established cardiovascular disease or diabetes.

ApoB/ApoA1 Ratio	Interpretation
Below 0.5	Very low cardiovascular risk
0.5 to 0.7	Favorable
0.7 to 0.9	Borderline elevated risk
0.9 to 1.1	High risk
Above 1.1	Very high risk

The INTERHEART study, which enrolled over 29,000 participants across 52 countries, found the ApoB/ApoA1 ratio was a stronger predictor of first myocardial infarction than LDL, HDL, total cholesterol, or any other single lipid measure. That is a meaningful finding. If you are only running a standard lipid panel, you are missing the ratio that best predicts the event you are trying to prevent.

To calculate it, you need both tests ordered on the same draw. Some ordering platforms include both by default in advanced cardiovascular panels. If yours does not, ask specifically for ApoB and ApoA1 as individual add-ons. A complete blood panel with advanced lipid markers will typically include both.

ApoA1 vs HDL: the practical difference

HDL cholesterol is measured by precipitating or blocking out non-HDL particles and measuring the remaining cholesterol. ApoA1 is measured directly via immunoturbidimetry or immunonephelometry, assays that detect the protein itself. The two metrics correlate reasonably well in healthy people but diverge in metabolically challenged states.

Here is where they split apart in clinical practice:

• Type 2 diabetes and insulin resistance: HDL can appear normal while ApoA1 is low and HDL particles are small, dense, and dysfunction. The glycation of ApoA1 also impairs its ability to activate ABCA1.
• Hypertriglyceridemia: High triglycerides accelerate the exchange of triglycerides into HDL particles (via CETP), producing triglyceride-rich, cholesterol-poor HDL. These particles are cleared faster, dropping both HDL and ApoA1, but ApoA1 tracks the functional loss more directly.
• Obesity: Central adiposity is associated with low ApoA1 independent of total HDL, partly due to increased ApoA1 catabolism.
• Statin therapy: Statins modestly raise ApoA1 (5 to 10%) while also raising HDL. The ApoA1 change more accurately reflects the functional improvement.

If your HDL is in the 40s or 50s but you have metabolic risk factors, running an ApoA1 is worth the extra cost. It may show a different picture.

A concrete example makes the divergence real. Picture two men, both with an HDL of 48 mg/dL, a number most people would wave through as fine. The first is lean and active, and his ApoA1 comes back at 140 mg/dL, matching that HDL. The second has a growing waistline and prediabetes, and despite the same HDL his ApoA1 is 98 mg/dL, because his HDL particles are cholesterol-heavy but protein-poor. On the standard panel they look identical. On ApoA1 they are not, and the second man is carrying the kind of dysfunctional HDL that a lipid panel alone would never reveal.

Low ApoA1 causes: what drives the protein down

Low ApoA1 results from either reduced synthesis or accelerated clearance. The common drivers are:

• Familial hypoalphalipoproteinemia: The most common genetic cause of chronically low HDL and ApoA1. It is typically autosomal dominant and often involves mutations in ABCA1 or the APOA1 gene itself.
• Tangier disease: A rare ABCA1 homozygous mutation that causes near-absent ApoA1 and HDL. Presents with orange tonsils and enlarged spleen in severe cases.
• Metabolic syndrome and insulin resistance: Insulin resistance upregulates CETP activity and accelerates ApoA1 catabolism via the kidneys.
• Hypertriglyceridemia: Elevated triglycerides remodel HDL particles and destabilize ApoA1, which then dissociates from the particle and is cleared by the kidneys.
• Smoking: Cigarette smoke oxidizes ApoA1, reducing its function and increasing its clearance rate. Quitting smoking raises ApoA1 within weeks.
• Chronic kidney disease: Proteinuria causes direct ApoA1 loss into the urine. This is why CKD patients have cardiovascular risk that exceeds what their lipid panels suggest.
• Inflammatory states: Acute-phase proteins displace ApoA1 from HDL during systemic inflammation (sepsis, lupus, rheumatoid arthritis). This is a temporary suppression, not a chronic state.
• Poor diet: Diets very high in refined carbohydrates and trans fats suppress ApoA1 synthesis. Mediterranean-pattern eating raises it.

Talk to a clinician about your results before attributing a low reading to any single cause, since several of these can stack.

How to raise ApoA1 levels: what actually works

The interventions with the most consistent evidence for raising ApoA1 in humans are not exotic. The challenge is that raising ApoA1 by improving particle function matters more than raising the number alone.

• Aerobic exercise: The single most reliable ApoA1 raiser in controlled trials. Three to five sessions per week of moderate-intensity cardio (brisk walking, cycling, swimming) raises ApoA1 by 5 to 15% over 12 weeks. Resistance training has a smaller effect.
• Alcohol reduction (or elimination): Moderate alcohol does modestly raise HDL and ApoA1, but the cardiovascular risk trade-off is now considered unfavorable by most guidelines. Heavy drinking suppresses ApoA1.
• Mediterranean diet: Olive oil, oily fish, legumes, and nuts consistently support higher ApoA1 compared to Western dietary patterns. The effect is partially mediated by reduced refined carbohydrate intake.
• Smoking cessation: Quitting raises ApoA1 meaningfully within 30 to 60 days.
• Weight loss: Even 5 to 10% body weight reduction raises ApoA1 in overweight individuals, likely through reduced CETP activity and improved insulin sensitivity.
• Niacin: Pharmacologic niacin (not the OTC supplement dose) raises ApoA1 by 15 to 30% but has not translated into reduced cardiovascular events in large trials and carries significant side effects. It is rarely prescribed today.
• Omega-3 fatty acids at prescription dose: High-dose EPA (icosapentaenoic acid, 4 g/day as in Vascepa) does not directly raise ApoA1 but reduces ApoA1 catabolism in hypertriglyceridemic patients.

How is the ApoA1 test done, and what can skew it?

The test itself is ordinary. A standard venous blood draw goes to the lab, where ApoA1 is measured directly by immunoturbidimetry or immunonephelometry. No special preparation, and no fasting requirement for the ApoA1 value on its own. What trips people up is timing, because several everyday states temporarily push the number in a direction that has nothing to do with your baseline risk.

• Acute illness or infection. ApoA1 is a negative acute-phase reactant, meaning it falls during infection, autoimmune flares, or any strong inflammatory hit. A reading drawn while you have the flu or right after surgery can look falsely low. Wait until you have been well for a couple of weeks before retesting.
• Recent heart attack or hospitalization. Levels drop in the days after a cardiac event, so an inpatient value is not your true baseline. Cardiologists reassess weeks later.
• Pregnancy and hormones. Estrogen raises ApoA1, so pregnancy, oral estrogen, or hormone therapy can lift the number. Note what you are taking when you interpret a result.
• Alcohol in the days before. A stretch of heavier drinking can transiently raise HDL and ApoA1, muddying the picture.
• Assay differences between labs. Because ApoA1 is measured directly and calibration varies, tracking your trend at the same lab is more reliable than comparing a Quest number to a Labcorp number.

The practical rule: draw ApoA1 when you are at a steady, well baseline, ideally alongside ApoB on the same sample, and repeat at the same lab so the trend is real rather than an artifact of the assay.

ApoA1 test cost, ordering, and insurance coverage

The ApoA1 test is a single immunoassay. It is available at Quest Diagnostics and Labcorp directly, and most hospital systems can run it on the same sample used for a standard draw.

Cash pricing without insurance typically runs $30 to $80 for ApoA1 alone. If you order it alongside ApoB to calculate the ratio, expect $60 to $150 for both tests combined through direct-to-consumer lab services. Prices vary significantly between platforms and geographic regions.

Insurance coverage is inconsistent. Medicare covers ApoA1 (CPT code 82101) when a physician documents cardiovascular risk assessment or dyslipidemia. Commercial payers often follow suit with a cardiology or lipid management diagnosis code, but preauthorization may be required. Without a clear diagnosis code, it may get filed as "not medically necessary" and you end up paying cash anyway.

For people getting a full cardiovascular workup, it is often smarter to capture a complete baseline in one draw. If you are getting blood drawn anyway, it is often smarter to capture a full baseline at once. Here is how a full-body panel compares when ApoA1 is included alongside ApoB, Lp(a), and the rest of the advanced lipid stack.

HSA and FSA funds can be used for lab tests ordered by a clinician. Some direct-to-consumer testing platforms also accept HSA/FSA cards for self-ordered panels.

What people get wrong about the ApoA1 test

The most common mistake is treating ApoA1 in isolation from ApoB. A single ApoA1 reading with no corresponding ApoB gives you half the story. You know the atheroprotective side but not the atherogenic load it is working against. A person with ApoA1 of 140 mg/dL and ApoB of 150 mg/dL (ratio 1.07) is at substantially higher risk than someone with ApoA1 of 110 mg/dL and ApoB of 70 mg/dL (ratio 0.64).

The second mistake is over-optimizing ApoA1 without addressing LDL particle count. Very high ApoA1 does not neutralize very high ApoB. Reverse cholesterol transport has limits, and the rate of plaque deposition from excess atherogenic particles can outpace the rate of efflux. Reducing ApoB through diet, exercise, and medication remains the primary cardiovascular intervention for most people.

Third: do not confuse ApoA1 with ApoA2. ApoA2 is the second most abundant protein on HDL and is sometimes measured in research settings. It does not have the same clinical utility and is not included in standard ApoA1 panels. They are distinct proteins with different roles.

The adiponectin test is another underused marker that pairs well with ApoA1 for assessing insulin-driven cardiovascular risk, particularly in patients with central obesity.

Who should get the ApoA1 test

The test has the most decision-making value in specific clinical situations rather than as a routine screen for everyone:

• Patients with persistently low HDL (below 40 mg/dL in men, below 50 in women) who need to understand whether the problem is structural or functional
• Anyone with metabolic syndrome, type 2 diabetes, or significant insulin resistance who wants a more accurate cardiovascular risk picture
• People with a strong family history of early cardiovascular disease where standard lipid panels look normal
• Patients already on statin therapy who want to confirm the therapy is improving HDL particle function, not just the cholesterol number
• Individuals with hypertriglyceridemia (triglycerides above 200 mg/dL) where ApoA1 is likely suppressed and the ApoB/ApoA1 ratio will be informative
• Anyone building a comprehensive cardiovascular baseline, particularly when reviewing the best biomarkers to test for long-term heart risk

It is less useful as a standalone test for someone with normal triglycerides, normal fasting glucose, and an HDL already in the 60s. In that person, the ApoA1 is almost certainly fine and adds little incremental data.

FAQ

What does a low ApoA1 result mean?

Low ApoA1 indicates a reduced concentration of functional HDL protein in circulation, which typically means impaired reverse cholesterol transport capacity. It is associated with higher cardiovascular risk, particularly when ApoB is simultaneously elevated. The most common causes are genetic predisposition, insulin resistance, hypertriglyceridemia, smoking, and inflammatory conditions. A low result warrants follow-up discussion with a clinician and usually prompts a look at the full lipid particle picture including ApoB.

Is ApoA1 the same as HDL cholesterol?

No. HDL cholesterol is the amount of cholesterol mass inside HDL particles. ApoA1 is the structural protein that makes up those particles. The two usually track together in healthy people but diverge in metabolic dysfunction. Someone with dysfunctional HDL can have a numerically normal HDL level and a low ApoA1, a pattern that carries real cardiovascular risk that HDL alone would not flag.

What is a good ApoB/ApoA1 ratio?

Below 0.8 is the general target for average-risk adults. Below 0.7 is the target for people with diabetes, established cardiovascular disease, or multiple risk factors. Very low ratios (below 0.5) are associated with very low cardiovascular event rates. The ratio requires both ApoB and ApoA1 to be measured on the same blood draw, so order them together.

Can you get an ApoA1 test without a doctor?

Yes. Several direct-to-consumer lab platforms in the US allow self-ordering of ApoA1 as a standalone add-on or as part of an advanced cardiovascular panel. Quest Diagnostics offers self-pay access through its QuestDirect portal, and several third-party services order through Quest or Labcorp on your behalf. Prices run $30 to $80 cash depending on the platform. Results go to you directly, and you can share them with a clinician for interpretation.

How often should you retest ApoA1?

For most people making lifestyle changes, retesting every 6 to 12 months gives enough time to see a meaningful response. If you have started a new medication that affects lipid metabolism (statin, fibrate, or prescription niacin) or made substantial dietary changes, a retest at 3 months is reasonable. Annual testing is sufficient for stable patients on established therapy. There is no clinical benefit to testing more frequently than every 3 months.

Does fasting affect ApoA1 test results?

ApoA1 is relatively stable across the fasting and postprandial state, unlike triglycerides which change significantly after eating. Most labs do not require fasting for an isolated ApoA1 test. However, if you are pairing it with a full lipid panel or other metabolic markers, fasting for 9 to 12 hours is standard practice and ensures all markers are drawn under comparable conditions. Check with your lab or ordering platform for their specific guidance.

What medications raise ApoA1?

Statins modestly raise ApoA1 (roughly 5 to 10%). Fibrates (fenofibrate, gemfibrozil) raise both ApoA1 and HDL, primarily by reducing triglycerides and thereby reducing ApoA1 catabolism. Pharmacologic niacin raises ApoA1 the most reliably (15 to 30%) but is infrequently prescribed today due to lack of outcome benefit in clinical trials. Some newer drugs, including CETP inhibitors in development, raise ApoA1 substantially, though their clinical benefit remains under study.

Is ApoA1 testing covered by Medicare?

Medicare Part B covers ApoA1 (CPT 82101) when a physician orders it for cardiovascular risk assessment or to evaluate known dyslipidemia, and the claim includes a covered diagnosis code. Coverage requires medical necessity documentation. Without the right diagnosis code, Medicare may deny the claim and the patient is billed cash rate. The albumin test is an example of another protein marker that Medicare covers under similar medical necessity rules, so the documentation pattern is familiar to most ordering clinicians.

Can ApoA1 be high? Is that a problem?

Very high ApoA1 (above 180 to 200 mg/dL) is generally not considered harmful. In most contexts, high ApoA1 reflects robust reverse cholesterol transport capacity and is associated with lower cardiovascular risk. There is no established upper clinical threshold above which ApoA1 becomes problematic. This distinguishes it from ApoB, where any reduction in the number of atherogenic particles is beneficial and there is no lower limit below which more harm occurs.

What other markers should I run alongside ApoA1?

The natural companion is ApoB, to calculate the ApoB/ApoA1 ratio. Beyond that, a meaningful cardiovascular baseline also includes Lp(a), high-sensitivity CRP, fasting insulin or HOMA-IR, and a standard lipid panel. The alkaline phosphatase test is occasionally added when liver or bone disease might be influencing lipid metabolism. Thinking about which markers to combine is exactly the kind of question the complete blood panel page addresses in depth.

Can an ApoA1 result be falsely low?

Yes. ApoA1 falls temporarily during infection, inflammatory flares, and in the days after surgery or a heart attack, because it behaves as a negative acute-phase reactant. A value drawn while you are acutely unwell can understate your true baseline. Retest a couple of weeks after you have fully recovered for a reading that reflects your steady state.

Does ApoA1 change with age and menopause?

Women run higher ApoA1 than men from puberty onward because estrogen increases its production. That advantage narrows after menopause as estrogen falls, which is part of why cardiovascular risk rises for women in the years after menopause. Interpreting an ApoA1 result alongside your life stage and any hormone therapy gives a truer picture than the number alone.